Metformin Pharmacology and Hemostatic Dynamics

Metformin is a first-line biguanide that exerts antihyperglycaemic effects primarily through activation of AMP-activated protein kinase (AMPK), reduction of hepatic gluconeogenesis and enhancement of peripheral glucose uptake. Its cellular uptake is mediated by organic cation transporters, and its pharmacokinetic profile is characterised by low bioavailability and a favourable safety record. Beyond glycaemic control, metformin influences vascular homeostasis by modulating endothelial function, reducing platelet hyperactivity and attenuating pro-coagulant pathways. Chemical modifications of the biguanide scaffold, notably introduction of sulfenamide or sulfonamide moieties, have been explored to optimise both pharmacological potency and haemostatic properties. These efforts aim to reduce gastrointestinal side-effects, improve tissue targeting and harness anti-thrombotic actions, thereby broadening metformin’s clinical utility in cardiovascular and thrombotic disorders.

Research from Nature Portfolio

Recent studies have evaluated a series of sulfenamide and sulfonamide derivatives of metformin for their effects on endothelial integrity and blood coagulation. Modified biguanides bearing n-butyl, p-nitro or o-nitro substituents were found to preserve endothelial cell viability while exerting pronounced anticoagulant effects. These compounds prolonged platelet-dependent thrombus formation under semi-physiological flow and reduced release of von Willebrand factor, without impairing tissue plasminogen activator release. Select derivatives also diminished tissue factor production and total blood thrombogenicity. Such findings demonstrate that targeted chemical modification of the metformin scaffold can yield dual-action agents that maintain glucose-lowering activity while enhancing anti-coagulant efficacy.

Metformin Pharmacology and Hemostatic Dynamics publication trend

The graph below shows the total number of articles in metformin pharmacology and hemostatic dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Biguanide: A class of compounds containing two linked guanidine groups; metformin is the prototypical biguanide used in diabetes treatment.

Organic cation transporter (OCT): Membrane proteins that facilitate cellular uptake of organic cations such as metformin.

Haemostasis: The physiological process that stops bleeding through vascular constriction, platelet aggregation and activation of the coagulation cascade.

Sulfonamide derivative: A compound in which a sulfonamide group is chemically incorporated into the metformin scaffold to alter its pharmacological properties.

Coagulation Factor X: A serine protease enzyme in the common coagulation pathway that converts prothrombin to thrombin, essential for fibrin clot formation.

References

1. Metformin derivatives – Researchers’ friends or foes?. Biochemical Pharmacology (2023).
2. Sulfenamide and Sulfonamide Derivatives of Metformin – A New Option to Improve Endothelial Function and Plasma Haemostasis. Scientific Reports (2019).
3. Structural Comparison of Sulfonamide-Based Derivatives That Can Improve Anti-Coagulation Properties of Metformin. International Journal of Molecular Sciences (2022).
4. Novel Sulfonamide-Based Analogs of Metformin Exert Promising Anti-Coagulant Effects without Compromising Glucose-Lowering Activity. Pharmaceuticals (2020).